Pro MedicusASX:PME +3.50%98 EV-to-FCF is 153.44 as of Jun. 25, 2026, which is 0% below its 10-year median of 153.45. GuruFocus rates ASX:PME with a GF Score™ of 98/100 and a GF Value™ of A$244.95 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 410 Healthcare Providers & Services companies, Pro Medicus ranks worse than 94.88% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pro Medicus's Enterprise Value is A$18,478.0 Mil.
Pro Medicus's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$120.4 Mil. Therefore, Pro Medicus's EV-to-FCF for today is 153.44.
The historical rank and industry rank for Pro Medicus's EV-to-FCF or its related term are showing as below:
ASX:PME'
s EV-to-FCF Range Over the Past 10 Years
Min: -340.31 Med: 153.45 Max: 2029.18
Current: 148.07
During the past 13 years, the highest EV-to-FCF of Pro Medicus was 2029.18. The lowest was -340.31. And the median was 153.45.
ASX:PME's EV-to-FCF is ranked worse than 94.88% of 410
companies
in the Healthcare Providers & Services industry
Industry Median: 17.47
vs ASX:PME: 148.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pro Medicus's PE Ratio (TTM) for today is calculated as:
Pro Medicus's share price for today is A$178.99.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pro Medicus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.243.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pro Medicus EV-to-FCF Related Terms
Pro Medicus EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pro Medicus's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Pro Medicus's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pro Medicus's EV-to-FCF falls into.
Pro Medicus's current Enterprise Value is A$18,478.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pro Medicus's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$120.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro Medicus (ASX:PME) has a EV-to-FCF of 153.44 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pro Medicus and its competitors. This is near median its historical median of 153.45. According to the industry distribution chart, Pro Medicus ranks #389 out of 410 companies in the Healthcare Providers & Services industry, placing it in the top 94.9%.
Is Pro Medicus' EV-to-FCF too high?
Pro Medicus' current EV-to-FCF of 153.44 is near median its 10-year median of 153.45. The Healthcare Providers & Services industry median EV-to-FCF is 17.47. Pro Medicus' value of 153.44 is 778.3% above this industry median. Based on the distribution chart, Pro Medicus ranks #389 out of 410 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pro Medicus has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' EV-to-FCF compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Pro Medicus ranks #389 out of 410 companies for EV-to-FCF. This places Pro Medicus in the lower half of its industry. The industry median EV-to-FCF is 17.47. Pro Medicus' value of 153.44 is 778.3% above this benchmark. While the company's 10-year median is 153.45 vs. the industry median of 17.47, Pro Medicus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.47, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current EV-to-FCF of 153.44 is 778.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pro Medicus and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current EV-to-FCF is 153.44, which is near median its own 10-year median of 153.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$244.95, compared to a current price of A$178.99 — trading 26.9% below its estimated fair value. The current EV-to-FCF is 153.44, which is near median its 10-year median of 153.45 and 778.3% above the Healthcare Providers & Services industry median of 17.47. Pro Medicus' overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current EV-to-FCF is 153.44 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (ASX:PME) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of A$178.99 is trading 26.9% below its estimated GF Value™ of A$244.95.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for ASX:PME:
EV-to-FCF: 153.44 (near median its 10-year median of 153.45)
GF Value™: A$244.95 vs. price of A$178.99 (26.9% below fair value)
Industry Position: 778.3% above the Healthcare Providers & Services median (#389 of 410)
No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
98GF Score
Get the complete analysis for ASX:PME
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PME has been successfully added to your 
